These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38091052)

  • 41. Outcome and prognostic factors in childhood B non-Hodgkin lymphoma from India: Report by the Indian Pediatric Oncology Group (InPOG-NHL-16-01 study).
    Rahiman EA; Bakhshi S; Deepam Pushpam ; Ramamoorthy J; Das A; Ghara N; Kalra M; Kapoor G; Meena JP; Siddaigarhi S; Thulkar S; Sharma MC; Srinivasan R; Trehan A
    Pediatr Hematol Oncol; 2022 Aug; 39(5):391-405. PubMed ID: 34978257
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
    Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
    Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial.
    Alexander S; Aupérin A; Bomken S; Csóka M; Kazanowska B; Chiang AK; Andres M; Uyttebroeck A; Burke GAA; Zsiros J; Pillon M; Bollard CM; Mussolin L; Verdu-Amoros J; Neven B; Barkauskas DA; Wheatley K; Patte C; Gross TG; Minard-Colin V; ;
    Lancet Haematol; 2023 Jun; 10(6):e445-e457. PubMed ID: 37094596
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 46. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
    Mead GM; Sydes MR; Walewski J; Grigg A; Hatton CS; Pescosta N; Guarnaccia C; Lewis MS; McKendrick J; Stenning SP; Wright D;
    Ann Oncol; 2002 Aug; 13(8):1264-74. PubMed ID: 12181251
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A prospective multicenter study investigating rituximab combined with intensive chemotherapy in newly diagnosed pediatric patients with aggressive mature B cell non-Hodgkin lymphoma (CCCG-BNHL-2015): a report from the Chinese Children's Cancer Group.
    Gao YJ; Fang YJ; Gao J; Yan J; Yang LC; Liu AG; Ju XL; Lu J; Han YL; Wang J; Xie M; Guo X; Tang JY
    Ann Hematol; 2022 Sep; 101(9):2035-2043. PubMed ID: 35829780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
    Jost LM; Jacky E; Dommann-Scherrer C; Honegger HP; Maurer R; Sauter C; Stahel RA
    Ann Oncol; 1995 May; 6(5):445-51. PubMed ID: 7545428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Excellent outcomes in children and adolescents with CNS
    Frazer JK; Li KJ; Galardy PJ; Perkins SL; Auperin A; Anderson JR; Pinkerton R; Buxton A; Gross TG; Michon J; Leverger G; Weinstein HJ; Harrison L; Shiramizu B; Barth MJ; Goldman SC; Patte C; Cairo MS
    Br J Haematol; 2019 Apr; 185(2):374-377. PubMed ID: 30117142
    [No Abstract]   [Full Text] [Related]  

  • 50. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
    Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
    Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.
    Meinhardt A; Burkhardt B; Zimmermann M; Borkhardt A; Kontny U; Klingebiel T; Berthold F; Janka-Schaub G; Klein C; Kabickova E; Klapper W; Attarbaschi A; Schrappe M; Reiter A;
    J Clin Oncol; 2010 Jul; 28(19):3115-21. PubMed ID: 20516455
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of
    Zhang Y; He D; He J; Huang W; Yang Y; Cai Z; Zhao Y
    Comput Math Methods Med; 2022; 2022():1080879. PubMed ID: 35096126
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Expression of p-AKT and p-mTOR in pediatric Burkitt lymphoma and their correlation with prognosis].
    Man J; Chen L; Zhai XW; Ma YY; Wang HS; Qian XW; Feng JY; Zhao J; Cao P; Lu FJ
    Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):156-161. PubMed ID: 32074729
    [No Abstract]   [Full Text] [Related]  

  • 54. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
    Dieckmann K; Pötter R; Hofmann J; Heinzl H; Wagner W; Schellong G;
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):644-52. PubMed ID: 12788169
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of pediatric B-cell non-Hodgkin's lymphomas at the Motol Hospital in Prague, Czech Republic: results based on the NHL BFM 90 protocols.
    Kavan P; Kabickova E; Gajdos P; Koutecky J; Kodet R; McClain KL
    Pediatr Hematol Oncol; 1999; 16(3):201-12. PubMed ID: 10326218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
    Roschewski M; Dunleavy K; Abramson JS; Powell BL; Link BK; Patel P; Bierman PJ; Jagadeesh D; Mitsuyasu RT; Peace D; Watson PR; Hanna WT; Melani C; Lucas AN; Steinberg SM; Pittaluga S; Jaffe ES; Friedberg JW; Kahl BS; Little RF; Bartlett NL; Fanale MA; Noy A; Wilson WH
    J Clin Oncol; 2020 Aug; 38(22):2519-2529. PubMed ID: 32453640
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.
    Cairo MS; Gerrard M; Sposto R; Auperin A; Pinkerton CR; Michon J; Weston C; Perkins SL; Raphael M; McCarthy K; Patte C;
    Blood; 2007 Apr; 109(7):2736-43. PubMed ID: 17138821
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
    Afify Z; Orjuela-Grimm M; Smith CM; Dalal M; Ford JB; Pillai P; Robles JM; Reddy S; McCormack S; Ehrhardt MJ; Ureda T; Alperstein W; Edington H; Miller TP; Rubinstein JD; Kavanaugh M; Bukowinski AJ; Friehling E; Rivers JM; Chisholm KM; Marks LJ; Mason CC
    Br J Haematol; 2023 Feb; 200(3):297-305. PubMed ID: 36454546
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
    Fayad L; Thomas D; Romaguera J
    Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S57-62. PubMed ID: 18284717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.